GlassScriptPhysician profile
Kinga M Huzella
NPI 1659371888
$6,201.84
in general payments reported to CMS, 2019-2025
27 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $376 · 2021: $688 · 2022: $836 · 2023: $1,477 · 2024: $1,293 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,912.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $993.49 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $934.70 | 2021-2025 | Acthar |
| Abbvie INC. | $654.74 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $488.09 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $453.02 | 2024-2025 | Xdemvy |
| Allergan, INC. | $347.80 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $286.17 | 2022-2025 | Purified Cortrophin Gel, Iluvien |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $245.70 | 2019-2021 | |
| Oyster Point Pharma, INC. | $216.15 | 2022-2024 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $196.05 | 2020-2025 | Clareon, Tryptyr, Rocklatan |
| Horizon Therapeutics Plc | $187.80 | 2021-2023 | Tepezza |
| Shire North American Group INC | $164.50 | 2019 | |
| New World Medical,INC. | $153.72 | 2023 | |
| Novartis Pharmaceuticals Corporation | $153.56 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $139.34 | 2019-2023 | Mentor Siltex Round Spectrum |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $112.71 | 2024-2025 | Vevye |
| Rxsight INC | $94.71 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Amgen INC. | $85.21 | 2024-2025 | Tepezza |
| Dompe US, INC. | $59.61 | 2021-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $53.62 | 2021 | |
| Biotissue Holdings INC. | $40.83 | 2019-2024 | |
| Eyevance Pharmaceuticals LLC | $28.72 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $28.45 | 2020 | |
| Sight Sciences, INC. | $24.86 | 2023 | Omni Surgical System |
| Thea Pharma INC. | $23.81 | 2023 | Iyuzeh |
| Kedrion Biopharma, INC. | $18.68 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Coopervision INC. | $15.80 | 2023 | Clariti Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinga Huzella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.